• br Brief overview of GSK inhibitors We

  2022-05-10

  

  Brief overview of GSK-3 inhibitors We will briefly summarize some of the key aspects about GSK-3 inhibitors. Additional details of GSK-3 inhibitors in clinical trials have been recently reviewed [5]. GSK-3 is a complicated target as it is involved in many biological processes from neurology, diab

• br Acknowledgements br Introduction Type

  2022-05-10

  

  Acknowledgements Introduction Type 2 diabetes is a progressive metabolic disorder which is characterised by chronic hyperglycaemia due to relative insulin deficiency, insulin resistance and increased hepatic glucose production [1]. The metabolism of glucose by glycolysis increases the ATP:ADP

• A few research articles described that PLGA could alone

  2022-05-10

  

  A few research articles described that PLGA could alone improve physiological activities in certain illnesses by exerting therapeutic effects. These reported therapeutic activities of PLGA can be appended to the hydrolysis products of PLGA lactate, glycolate, and H+. We will recapitulate their respe

• It has been proposed that

  2022-05-10

  

  It has been proposed that HCA1 may be a better target than HCA2 to treat dyslipidemia and to prevent progression of atherosclerosis, because HCA1 is less widely expressed, and HCA1 activation does not result in flushing. However, since the antilipolytic effects mediated by HCA2 appear to be not the

• br Results and discussion br Conclusions In summary we

  2022-05-10

  

  Results and discussion Conclusions In summary, we generated analogues of the hit compounds 1–3, studied their structure–activity relationships, and created a series of highly potent GPR55 agonists. The most potent agonists among the series were 17a-b, 17e, 17g and 17l with EC50 values below 10

• Recently we suggested that KYNA an endogenous GPR

  2022-05-10

  

  Recently, we suggested that KYNA – an endogenous GPR35 agonist could be produced in a human cornea since we showed the presence of the enzymes that catalyze the synthesis of KYNA – kynurenine aminotransferases I-III in corneal epithelium, stroma and endothelium (). Therefore, these findings provided

• br Experimental br Acknowledgments This research was

  2022-05-10

  

  Experimental Acknowledgments This research was supported by the Korea Research Foundation (2013R1A1A2007509). The authors thank to Dr. Moon Ho Son (Dong-A Pharm. Co. Ltd) for hGPR119 agonist activity assay. We also thank to Pharmacal Research Institute and Central Laboratory of Kangwon Nationa

• br Author contributions br Acknowledgements The

  2022-05-10

  

  Author contributions Acknowledgements The work was financially supported by a grant from the Investigator-Initiated Studies Program (Ref. #38124) from Merck Sharp & Dohme, and, in part, from Research Grants Council of the Hong Kong Special Administrative Region, China (Ref. No.: 14110314), awa

• Gp induces cell death by apoptotic mechanisms and

  2022-05-10

  

  Gp120 induces cell death by apoptotic mechanisms and increases intracellular Ca, and activates messengers related to cell death. Intracellular mechanisms of neuronal damage are mainly a consequence of the activation of the N-methyl-d-aspartate receptor (NMDAR) [2], [5], which induces excitotoxicity

• br Material and methods br Results br Discussion The inhibit

  2022-05-10

  

  Material and methods Results Discussion The inhibitory action of a GABA agonist, muscimol, on the level of mRNA encoding GnRH in the POA-hypothalamus [25] of follicular-phase sheep has suggested that at the hypothalamic level GABA may exert a suppressive effect on subsequent steps of the Gn

• To confirm that these were bona fide interactions we investi

  2022-05-10

  

  To confirm that these were bona fide interactions, we investigated whether the potassium channel subunits or Tmem263 formed complexes with GLT-1 or DAT after immunoprecipitation. Lysates of HEK-293 cells previously cotransfected with HA-GLT-1 or HA-DAT, and either YFP-Kv7.3, YFP-Kv7.2 or YFP-Kv7.5 w

• br Acknowledgements This research was

  2022-05-10

  

  Acknowledgements This research was funded by Ministry of Education Malaysia (MOE), and supported by the Department of Nutrition, Exercise & Sports, Department of Drug Design, University of Copenhagen, Denmark and Universiti Malaysia Pahang (UMP), Malaysia. HPLC equipment used for high-resolution

• br Preclinical development of GIP

  2022-05-09

  

  Preclinical development of GIP agonists Since the action of DPP IV is not limited to GIP, the most specific pharmacological approach for GIP would be modification at the N-terminus to disrupt DPP IV-mediated degradation. Indeed, it has been shown that GIP analogues with N-terminal modifications a

• Polymerisation of HbS initiates the clinical complications

  2022-05-09

  

  Polymerisation of HbS initiates the clinical complications of SCD (Bunn and Forget, 1986). The resulting sequelae are multiple and diverse, and their individual impact on pathogenesis is difficult to elucidate. Early changes include altered red cell membrane permeability (Gibson and Ellory, 2002, Le

• For the two KO models CX and CX fluorescence recovery

  2022-05-09

  

  For the two KO models (CX30 and CX43), fluorescence recovery is almost always best fitted with a 2-component exponential (Fig. 6A and D). Statistical analysis of the parameters (Table 1) shows that in both cases the two time scales and the fraction of recovery associated with the fast intracellular

15677 records 417/1046 page Previous Next First page 上5页 416417418419420 下5页 Last page